Cargando…

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal disorders of a hematopoietic stem cell, characterized by an abnormal proliferation of largely mature cells driven by mutations in JAK2, CALR, and MPL. All these mutations lead to a constitutive activation of the JAK-STAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loscocco, Giuseppe G., Coltro, Giacomo, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391705/ https://www.ncbi.nlm.nih.gov/pubmed/34440731 http://dx.doi.org/10.3390/cells10081962

Ejemplares similares

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
por: Malato, Alessandra, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
por: Mannelli, Francesco, et al.
Publicado: (2022)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
por: Vianello, Fabrizio, et al.
Publicado: (2011)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis
por: Rosti, Vittorio, et al.
Publicado: (2010)

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
por: Jang, Mi-Ae, et al.
Publicado: (2020)

Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics
por: Nann, Dominik, et al.
Publicado: (2021)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Myeloid sarcoma: more and less than a distinct entity
por: Loscocco, Giuseppe G., et al.
Publicado: (2023)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5t75c4a6ap77uraiuqjs0s567u